[HTML][HTML] A pilot trial targeting the ICOS–ICOS-L pathway in nonhuman primate kidney transplantation
DJ Lo, DJ Anderson, M Song, F Leopardi… - American Journal of …, 2015 - Elsevier
Costimulation blockade with the B7-CD28 pathway-specific agent belatacept is now used in
clinical kidney transplantation, but its efficacy remains imperfect. Numerous alternate
costimulatory pathways have been proposed as targets to synergize with belatacept, one of
which being the inducible costimulator (ICOS)–ICOS ligand (ICOS-L) pathway. Combined
ICOS–ICOS-L and CD28-B7 blockade has been shown to prevent rejection in mice, but has
not been studied in primates. We therefore tested a novel ICOS-Ig human Fc-fusion protein …
clinical kidney transplantation, but its efficacy remains imperfect. Numerous alternate
costimulatory pathways have been proposed as targets to synergize with belatacept, one of
which being the inducible costimulator (ICOS)–ICOS ligand (ICOS-L) pathway. Combined
ICOS–ICOS-L and CD28-B7 blockade has been shown to prevent rejection in mice, but has
not been studied in primates. We therefore tested a novel ICOS-Ig human Fc-fusion protein …